LIVINGSTON, NJ --(Marketwired - December 12, 2017) - Milestone Scientific Inc . (
Leslie Bernhard, Chairman of the Board, and Interim Chief Executive Officer, commented, "We were very pleased with the turnout at both our booth and Henry Schein's Exclusive Products booth, both of which featured The Wand® STA®, and further illustrates the growing enthusiasm around our instrument. Since partnering with Henry Schein as our exclusive North American distributor, we have seen strong domestic sales growth in both the instrument and handpieces. This is further evidenced by the fact that leading children's hospitals are adopting The Wand® STA® for their pediatric dentistry patients and even incorporating it into the curriculum for pediatric residency programs."
"The technology behind The Wand® STA®, Dynamic Pressure Sensing -- DPS®, is the same patented platform technology behind our newly developed computerized cosmetic Botox injection system. It was clear from the exposition that dentists across the country are looking to grow practice revenue by providing additional cosmetic services, beyond implants and veneers, such as aesthetic injections with Botulinum toxin. Our new cosmetic instrument is designed to deliver Botulinum toxin in a precise and comfortable way. We believe our existing dental distribution channel will be one of many launch points for our new cosmetic injection system."
At the meeting, Milestone continued to support the ongoing educational needs of dentists by offering its innovative continuing education, CEU-generating course on the Quality of Pain Control.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com .
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020
